How much funding has Yarrow Biosciences raised?

Yarrow Biosciences has raised $200.0M in total funding, most recently a Series A round.

Who are Yarrow Biosciences's investors?

Yarrow Biosciences's investors include RTW Investments, OrbiMed, Janus Henderson Investors, venBIO Partners, Logos Capital, LifeSci Venture Partners.

When was Yarrow Biosciences founded?

Yarrow Biosciences was founded in 2021.

Where is Yarrow Biosciences headquartered?

Yarrow Biosciences is headquartered in New York, New York, United States.

What industry is Yarrow Biosciences in?

Yarrow Biosciences operates in Biotech, Healthcare.

How many employees does Yarrow Biosciences have?

Yarrow Biosciences has 1-10 employees.

Yarrow Biosciences

First-in-class anti-TSHR antibody for autoimmune thyroid diseases

New York, United States · Founded 2021 · $200.0M raised

Biotech

Healthcare

Headquarters: New York, New York
Employees: 1–10
Founded: 2021
Business Model: B2B

Website: yarrowbioscience.com
Total Funding: $200.0M
Last Round: $200.0M Series ADec 2025
Rounds: 1

About

Yarrow Bioscience is a clinical-stage biotechnology company developing a first-in-class anti-TSHR antibody (YB-101/GS-098) targeting Graves' disease and thyroid eye disease. Signed $1.37B licensing with GenSci; reverse merger with Vyne Dec 2025.

Summary

Yarrow Biosciences is a Biotech company based in New York, United States, founded in 2021. It has raised $200.0M in total across 1 round, most recently a $200.0M Series A round in Dec 2025. Investors include RTW Investments, OrbiMed and Janus Henderson Investors.